Antabuse Moves into Clinical Trial for People with RP
Listen now
Description
Researchers believe the FDA-approved drug can reduce the hyperactivity of ganglion cells to improve vision.
More Episodes
Dr. Peter Campochiaro, a clinician-scientist and the Eccles Professor of Ophthalmology and Neuroscience at the Johns Hopkins University School of Medicine, talks to host Ben Shaberman about N-acetylcysteine (NAC), a drug that shows promise for preserving cone vision (central vision and acuity) in...
Published 06/07/24
Published 06/07/24
Peter Wallsten, a veteran newspaper journalist and head of investigative reporting at The Washington Post, talks to host Ben Shaberman about his evolving career as a reporter and editor and the impact that Stargardt disease has had on his journey and ambitions. Peter also reflects on recently...
Published 05/24/24